Top Asian Stocks For 2014

Beacon Pointe Wealth Advisors has added registered investment advisor Pacific Pointe in a rollup partnership that adds $175 million in assets under management to the firm, BPWA announced Monday.

Pacific Pointe, based in Santa Barbara, is the fourth California location to be added to BPWA, a Beacon Pointe Advisors RIA based in Newport Beach, Calif. The expansion marks BPWA’s second deal in five months and its fifth addition of an advisory firm to BPWA.

BPWA projects that it will reach nearly $1 billion in total AUM by year end, and it plans to continue its California expansion while adding to its geographic footprint in Denver, Boston and Richmond. It is 100% owned by each of the advisor partners that have joined RIA Beacon Pointe Advisors, which has AUM of $5.8 billion.

The advisor partners at BPWA do not hesitate to use the term “rollup,” an industry term that other firms with a long-term home for advisors have shied away from using, according to Beacon Pointe Wealth Advisors President Matt Cooper, whose Alliance for RIAs (aRIA) study group was named to Investment Advisor’s IA 25 list in 2013.

Top Asian Stocks For 2014: Allstate Corp (ALL)

The Allstate Corporation (Allstate), November 5, 1992, is a holding company for Allstate Insurance Company. The Company’s business is conducted principally through Allstate Insurance Company, Allstate Life Insurance Company and their affiliates. It is engaged, principally in the United States, in the property-liability insurance, life insurance, retirement and investment product business. Allstate’s primary business is the sale of private passenger auto and homeowners insurance. The Company also sells several other personal property and casualty insurance products, select commercial property and casualty coverages, life insurance, annuities, voluntary accident and health insurance and funding agreements. Allstate primarily distributes its products through exclusive agencies, financial specialists, independent agencies, call centers and the Internet. It conducts its business primarily in the United States. Allstate has four business segments: Allstate Protection, Allstate Financial, Discontinued Lines and Coverages and Corporate and Other. The Company is a personal lines insurer in the United States. Customers can access Allstate products and services, such as auto insurance and homeowners insurance through nearly 12,000 exclusive Allstate agencies and financial representatives in the United States and Canada. In October 2011, the Company acquired Esurance and Answer Financial from White Mountains Insurance Group.

 

ALLSTATE PROTECTION SEGMENT

 

In this segment, the Company principally sells private passenger auto and homeowners insurance through agencies and directly through call centers and the Internet. These products are marketed under the Allstate, Encompass and Esurance brand names. The Allstate Protection segment also includes a separate organization called Emerging Businesses, which comprises Business Insurance (commercial products for small business owners), Consumer Household (specialty products including motorcycle, boat, renters and condominium insurance policies), Allstate Dealer Services (insurance and non-insurance products sold primarily to auto dealers), Allstate Roadside Services (retail and wholesale roadside assistance products) and Ivantage (insurance agency). The Company also participates in the involuntary or shared private passenger auto insurance business in order to maintain its licenses to do business in many states. In some states, Allstate exclusive agencies offer non-proprietary property insurance products. Allstate brand auto and homeowners insurance products are sold primarily through Allstate exclusive agencies and serve customers who prefer local personal advice and service and are brand-sensitive. In most states, customers can also purchase certain Allstate brand personal insurance products, and obtain service, directly through call centers and the Internet.

 

During the year ended December 31, 2011, total Allstate Protection premiums written were $25.98 billion. Its broad-based network of approximately 10,000 Allstate exclusive agencies in approximately 9,700 locations in the United States produced approximately 86% of the Allstate Protection segment’s written premiums in 2011. It provides personal property and casualty insurance products through independent agencies in the United States. Additionally, Allstate distribution, through brokering arrangements, offers non-proprietary products to consumers when an Allstate product is not available.

 

ALLSTATE FINANCIAL SEGMENT

 

Allstate Financial segment provides life insurance, retirement and investment products, and voluntary accident and health insurance products. Its principal products are interest-sensitive, traditional and variable life insurance; fixed annuities, including deferred and immediate; and voluntary accident and health insurance. Its institutional products consist of funding agreements sold to unaffiliated trusts that use them to back medium-term notes issued to institutional and individual investors. Banking products and services were offered to customers through the Allstate Bank through September 2011. In 2011, after receiving regulatory approval to voluntarily dissolve, Allstate Bank ceased operations.

 

The Company sells Allstate Financial products to individuals through multiple intermediary distribution channels, including Allstate exclusive agencies and exclusive financial specialists, independent agents, specialized structured settlement brokers and directly through call centers and the Internet. The Company sells products through independent agents affiliated with approximately 125 master brokerage agencies. Independent workplace enrolling agents and Allstate exclusive agencies also sell its voluntary accident and health insurance products primarily to employees of unaffiliated businesses. Its mortgage loan portfolio, which is primarily held in the Allstate Financial portfolio, totaled $7.14 billion as of December 31, 2011

 

Allstate Financial, through several companies, is authorized to sell life insurance and retirement products in all 50 states, the District of Columbia, Puerto Rico, the United States, Virgin Islands and Guam. Allstate Financial distributes its products to individuals through multiple distribution channels, including Allstate exclusive agencies and exclusive financial specialists, independent agents (including master brokerage agencies and workplace enrolling agents), specialized structured settlement brokers and directly through call centers and the Internet.

 

OTHER BUSINESS SEGMENTS

 

The Company’s Corporate and Other segment consistsof holding company activities and certain non-insurance operations. It’s Discontinued Lines and Coverages segment includes results from insurance coverage that it no longer writes and results for certain commercial and other businesses in run-off. Its exposure to asbestos, environmental and other discontinued lines claims is presented in the segment. The segment also includes the historical results of the commercial and reinsurance businesses sold in 1996.

Advisors’ Opinion:

  • [By John Kell]Allstate Corp.(ALL) said its fourth-quarter profit more than doubled, boosted in part by rising insurance policies in several units and fewer catastrophes.
  • [By Wallace Witkowski]Insurers such as Aflac Inc. (AFL) , Allstate Corp. (ALL) , Aetna Inc. (AET) , Cigna Corp. (CI)  and Prudential Financial Inc. (PRU)  will also report, along with exchange operators Nasdaq OMX Group Inc. (NDAQ)  and CME Group Inc. (CME) .Â
  • [By Laura Brodbeck]Wednesday

    Earnings Expected: Allstate Corporation (NYSE: ALL), Green Mountain Coffee Roasters, Inc. (NASDAQ: GMCR), Humana Inc. (NYSE: HUM), GlaxoSmithKline PLC (NYSE: GSK), Twitter, Inc. (NYSE: TWTR), Walt Disney Company (NYSE: DIS) Economic Releases Expected: German trade balance, Italian unemployment, eurozone retail sales, eurozone unemployment rate, Irish retail sales, US crude oil inventories, US FOMC minutes, Chinese CPI, Chinese PPIThursday

Top Asian Stocks For 2014: Covidien PLC (COV)

Covidien Public Limited Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. It operates its businesses through three segments: Medical Devices, which includes the development, manufacture and sale of endomechanical instruments, energy devices, soft tissue repair products, vascular products, oximetry and monitoring products, airway and ventilation products; Pharmaceuticals, which includes the development, manufacture and distribution of specialty pharmaceuticals and active pharmaceutical ingredients, and Medical Supplies, SharpSafety products and original equipment manufacturer products. In May 2012, it acquired Newport Medical Instruments, Inc. In May 2012, it acquired superDimension, Ltd. In June 2012, the Company acquired Oridion Systems Ltd. In October 2012, its Mallinckrodt acquired CNS Therapeutics, Inc. In January 2013, the Company acquired CV Ingenuity. Advisors’ Opinion:

  • [By Peter Stephens]As mentioned, sector peers such as Stryker (NYSE: SYK  ) and Covidien (NYSE: COV  ) are slightly ahead of St. Jude on EPS growth forecasts, with both companies forecast to increase EPS by 8% in 2014. Meanwhile, they are expected to increase EPS by 10% and 11%, respectively, in 2015. (Note that St. Jude and Stryker have calendar year-ends and Covidien has a September year-end.)
  • [By Laura Brodbeck]Friday

    Earnings Expected From: Covidien plc. (NYSE: COV), Eldorado Gold Corporation (NYSE: EGO), Vaalco Energy Inc. (NYSE: EGY) Economic Releases Expected:  US Wholesale Trade, US non-farm payrollsPosted-In: Bank Of England European Central Bank Federal ReserveNews Eurozone Previews Global Economics Federal Reserve Markets Trading Ideas Best of Benzinga

  • [By Keith Speights]Product recalls usually hurt companies. Covidien’s (NYSE: COV  ) shares were temporarily affected by the company’s recall of surgical tools last year. Johnson & Johnson stock took a hit in 2010 and early 2011 partially due to recalls of several products.Â
  • [By Dan Caplinger]Yet the episode led to criticism of Intuitive Surgical in other arenas. Last month, the president of a major group of OB/GYNs said that using robotic systems for hysterectomy procedures — a significant area of potential growth for the company — lacked data showing its usefulness and made procedures far more expensive. That could reduce sales and have an impact not just toward the end of last quarter but for future periods as well. Moreover, you can expect traditional medical-instrument makers Johnson & Johnson (NYSE: JNJ  ) and Covidien (NYSE: COV  ) to step in to take advantage of the situation, as they stand to benefit substantially if robotics are shown to be inferior. Both J&J and Covidien supply more traditional instruments and supplies for surgical procedures, and regulators are more familiar with their safety profiles.

Top Asian Stocks For 2014: NCR Corp (NCR)

NCR Corporation (NCR), incorporated on January 02, 1926, is a technology company, which provides products and services, which enable businesses to connect, interact and transact with their customers and enhance their customer relationships by addressing consumer demand for convenience, value and individual service. NCR’s portfolio of self-service and assisted-service solutions serve customers in the financial services, retail, hospitality, travel and gaming and entertainment industries and include automated teller machines (ATMs), self-service kiosks and point of sale (POS) devices, as well as software applications, which can be used by consumers to enable them to interact with businesses from their computer or mobile device. NCR complements these product solutions by offering a portfolio of services to help customers design, deploy and support its technology tools. NCR also resells third-party networking products and provides related service offerings in the telecommunications and technology sectors. The Company operates in four segments: Financial Services, Retail Solutions, Hospitality (formerly Hospitality and Specialty Retail), and Emerging Industries. Its product and service offerings include ATMs and Other Financial Products, Self-Service Kiosks, Point of Sale, Check and Document Imaging, Services, and Consumables. In June 2012, the Company acquired POS Integrated Solutions, a reseller of the NCR Aloha solution for restaurants; Wyse Sistemas de Informatica Ltda., a provider of software solutions, including the Colibri suite of hospitality software, and Radiant Distribution Solutions (RDS), a NCR Hospitality hardware distribution partner. In June 2012, Coinstar, Inc.’s wholly owned subsidiary, Redbox Automated Retail, LLC, acquired certain assets of the Company’s self-service entertainment DVD kiosk business. In November 2012, NCR acquired Retalix Ltd. In January 2013, the Company purchased uGenius Technology, Inc. In February 2013, the Company acquired Retalix Ltd. In January 2014, NCR Corp completed the acquisition of Digital Insight Corporation.

 

ATMs and Other Financial Products

 

The Company provides financial institutions, retailers and independent deployers with financial-oriented self-service technologies, such as ATMs, cash dispensers, and software solutions, including the APTRA application suite as well as consulting services related to ATM security, software and bank branch optimization. ATM and other financial product solutions are designed to quickly and reliably process consumer transactions and incorporate advanced features such as automated check cashing/deposit, automated cash deposit, Web-enablement and bill payment (including mobile bill payment).

 

Point of Sale

 

The Company provides retail and hospitality oriented technologies such as point of sale terminals, bar-code scanners, software and services to companies and venues worldwide. Combining its retail and hospitality industry, software and hardware technologies, and consulting services, its solutions are designed to enable cost reductions and improve operational efficiency while increasing customer satisfaction.

 

Self-Service Kiosks

 

The Company provides self-service kiosks to the retail, hospitality, travel and gaming, and entertainment industries and also owns and operates self-service kiosks in the entertainment industry. Its versatile kiosk solutions can support retail self-service functions, including self-checkout, wayfinding, bill payment and gift registries. It provides self check in/out kiosk solutions to airlines, hotels and casinos, which allows guests to check-in/out without assistance. These solutions create pleasant and convenient experiences for consumers and enable its customers to reduce costs. Its kiosks for the hospitality industry provide consumers the ability to order and pay at restaurants while enabling its customers to streamline order processing and reduce operating costs.

 

Check and Document Imaging

 

The Company’s check and document imaging offerings provide end-to-end solutions for both traditional paper-based and image-based check and item processing. These solutions utilize advanced image recognition and workflow technologies to automate item processing, helping financial institutions efficiency and reduce operating costs. Consisting of hardware, software, consulting and support services, its comprehensive check and document imaging solutions enable check and item-based transactions to be digitally captured, processed and retained within a flexible, scalable environment.

 

Consumables

 

The Company develop, produce and market a complete line of printer consumables for various print technologies. These products include two-sided thermal paper (2ST), paper rolls for receipts in ATMs and POS solutions, inkjet and laser printer supplies, thermal transfer and ink ribbons, labels, laser documents, business forms, and specialty media items such as photo and presentation papers. Consumables are designed to optimize operations and improve transaction accuracy, while reducing overall costs.

Services

 

The Company provides maintenance and support services for its product offerings and also provides other services, including site assessment and preparation, staging, installation and implementation, systems management and complete managed services. It also offers a range of software and services, such as Software-as-a-Service, hosted services, and online, mobile and transactional services and applications, such as bill pay and digital signage. In addition, it is also focused on expanding the resale of third party networking products and related service offerings to a base of customers in the telecommunications and technology sectors and servicing third-party computer hardware from select manufacturers.

 

The Company competes with Diebold, Inc., Wincor Nixdorf GmbH & Co., Hyosung, IBM, Wincor, Fujitsu, Hewlett-Packard, ToshibaTec, Dell, Honeywell, Micros Systems, Verifone, Datalogic, SITA and IER.

Advisors’ Opinion:

  • [By MARKETWATCH]SAN FRANCISCO (MarketWatch) — Wall Street hedge-fund investor David Einhorn was active in the last quarter of 2013, taking new stakes in technology and energy companies, while trimming existing holdings in insurer Aetna (AET) , NCR Corp (NCR) and WPX Energy (WPX) , according to an SEC filing Friday. Einhorn’s Greenlight Capital picked up stakes in Anadarko Petroleum (APC) , BP (BP) , McDermott Intl. (MDR) , Micron Technolgy (MU) and Take-Two Interactive (TTWO) , according to the latest 13F filing. He trimmed stakes in Aetna, Einstein Noah (BAGL) and WPX Energy, according to the filing.
  • [By Jake L’Ecuyer]Equities Trading DOWN
    Shares of NCR Corp (NYSE: NCR) fell on Friday’s session, dropping 8.40 percent to $32.04 despite beating on earnings Thursday after the company guided its fiscal year 2014 EPS guidance below street expectations.
  • [By Holly LaFon]NCR Corporation (NCR) was the Fund’s largest detrac tor during the fourth quarter, falling over 14 percent and detracting 25 basis points of return . The nancial technology company delivered a slightly weaker than expected quarter t hat surprised us as well as the Street. They reafrmed guidance which implies a strong fourth qu arter and suggested that cash ows will continue to be cautiously managed. Since we like th e business and valuation, as well as the improved balance sheet, we are inclined to stay the course.

Top Asian Stocks For 2014: Continental Resources Inc. (CLR)

Continental Resources, Inc. engages in the exploration, development, and production of crude oil and natural gas primarily in the north, south, and east regions of the United States. The company primarily sells its oil and natural gas production to end users, as well as to midstream marketing companies or oil refining companies at the lease. As of December 31, 2011, its estimated proved reserves were 508.4 million barrels of crude oil equivalent, with estimated proved developed reserves of 205.2 million barrels of crude oil equivalent. The company had interests in 3,255 wells and served as the operator of 2,082 of these wells. Continental Resources, Inc. was founded in 1967 and is headquartered in Enid, Oklahoma.

Advisors’ Opinion:

  • [By Robert Rapier]So did the latest set of strong quarterly numbers reported last week by two of our favorite Bakken oil drillers, Aggressive Portfolio holding Continental Resources (NYSE: CLR) and Growth Portfolio pick Whiting Petroleum (NYSE: WLL). They have returned 42 percent and 37 percent, respectively, since we recommended them a year ago, and by the looks of the latest numbers are far from done. Â
  • [By Jay Yao]The benefit of being nimble
    $100 billion is about the cumulative market cap of Pioneer Natural Resources  (NYSE: PXD  ) , EOG Resources  (NYSE: EOG  ) , and Continental Resources  (NYSE: CLR  ) . $100 billion is also roughly half of what ExxonMobil spent on share buybacks over the past 10 years.Â
  • [By Paul Ausick]Independent producer Continental Resources Inc. (NYSE: CLR) is also down about 2% at $107.67 in a 52-week range of $72.35 to $121.78. The stock’s annual high was posted in mid-October. Continental just reported a 38% increase in its proved reserves to 1.08 billion barrels, primarily in the Bakken play in North Dakota. The stock’s price target is $131.45 and at the current price that implies a potential gain of 22%. The forward P/E ratio is 15.24 based on 2014 earnings.
  • [By Lee Jackson]Continental Resources Inc. (NYSE: CLR) was recently upgraded and makes the list of top names to buy. The company is one of the top names in the Bakken shale and the analysts are expecting a slow, but steady increase in production levels. The Merrill Lynch price target is posted at $145, and the consensus is at $131.45. Continental closed Friday at $106.91. A move to the target represents a 36% gain for investors.

Top Asian Stocks For 2014: Biodel Inc (BIOD)

Biodel Inc. (Biodel), incorporated on December 3, 2003, is a development-stage speciality biopharmaceutical company focused on the development and commercialization of treatments for diabetes. The Company develops its product candidates by applying its formulation technologies to existing drugs. Its advanced program involves developing formulations of injectable recombinant human insulin (RHI). In addition to its ultra-rapid-acting insulin formulations, the Company has developed prototype formulations of a liquid glucagon, a basal insulin and a glucose responsive insulin, in each case for use by patients with diabetes. RHI-based formulation known as Linjeta was the subject of a New Drug Application (NDA).

 

The Company has two pivotal Phase III clinical trials with its preferred commercial formulation of Linjeta prior to re-submitting the NDA. In August 2011, it completed patient visits and analyzed top-line data from the first Phase 1 clinical trial of two RHI-based formulations. The trial was a single-center, randomized, double-blind, three-period crossover trial in 18 subjects with Type 1 diabetes. The purpose of the trial was to evaluate the pharmacokinetic and pharmacodynamic characteristics and injection site toleration of BIOD-105 and BIOD-107, as compared to the insulin analog marketed as Humalog. The Company conducted Phase I, Phase II and Phase III clinical trials comparing the performance of its Linjeta formulation of RHI to either Humulin, which is a branded formulation of RHI or Humalog. Its pivotal Phase III clinical trials were open-label, parallel group, randomized trials conducted at centers in the United States, Germany and India.

 

The Company competes with Eli Lilly, Novo Nordisk, Sanofi-Aventis, Halozyme Therapeutics, Inc. and MannKind Corporation.

Advisors’ Opinion:

  • [By Roberto Pedone]One under-$10 specialty biopharmaceutical player that’s starting to trend within range of triggering a big breakout trade is Biodel (BIOD), which is focused on the development and commercialization of innovative treatments for diabetes. This stock has been hit hard by the bears over the last three months, with shares down by 24%.

    If you take a look at the chart for Biodel, you’ll notice that this stock is ripping higher here right off its 50-day moving average of $2.32 a share with strong upside volume. Volume on Thursday has so far registered over 750,000 shares, which is well above its three-month average action of 445,084 shares. This move is quickly pushing shares of BIOD within range of triggering a big breakout trade.

    Traders should now look for long-biased trades in BIOD if it manages to break out above some near-term overhead resistance levels at $2.52 to $2.60 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 445,084 shares. If that breakout triggers soon, then BIOD will set up to re-test or possibly take out its next major overhead resistance levels $3 to its 200-day moving average of $3.39 a share. Any high-volume move above $3.39 will then give BIOD a chance to tag $4 a share.

    Traders can look to buy BIOD off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support at $2.10 a share. One can also buy BIOD off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Top Asian Stocks For 2014: Organovo Holdings Inc (ONVO)

Organovo Holdings, Inc. (Organovo), formerly Real Estate Restoration & Rental, Inc., incorporated in 2007, is a development-stage company. The Company has developed and is commercializing a platform technology for the generation of three-dimensional (3D) human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. On December 28, 2011, Real Estate Restoration and Rental, Inc.’s (RERR) entered into an Agreement and Plan of Merger, pursuant to which RERR merged with its, wholly owned subsidiary, Organovo (Merger Sub). On February 8, 2012, the Company merged with and into Organovo Acquisition Corp. (Acquisition Corp.), a wholly owned subsidiary of Organovo, with the Company surviving the merger as a wholly owned subsidiary of Organovo Holdings (the Merger). As a result of the Merger, Organovo acquired the business of Organovo, Inc.

 

The Company has collaborative research agreements with Pfizer, Inc. (Pfizer) and United Therapeutic Corporation (Unither). As of March 31, 2012, it has five federal grants, including Small Business Innovation Research grants and developed the NovoGen MMX Bioprinter (its first-generation 3D bioprinter). The Company is engaged in the development of specific 3D human tissues to aid Pfizer in discovery of therapies in two areas of interest. In addition, in October 2011, it entered into a research agreement with Unither to establish and conduct a research program to discover treatments for pulmonary hypertension using its NovoGen MMX Bioprinter technology. Additionally, under the research agreement with Unither, the Company granted Unither an option to acquire from the Company a worldwide, royalty-bearing license in certain intellectual property created under the research agreement solely for use in the treatment or prevention of pulmonary hypertension and all other lung diseases.

 

The Company’s NovoGen MMX Bioprinter is an automated device that enables the fabrication of three-dimensional (3D) living tissues comprised of mammalian cells. A custom graphic user interface (GUI) facilitates the 3D design and execution of scripts that direct precision movement of the dispensing heads to deposit cellular building blocks (bio-ink) or supporting hydrogel. The Company is using a third party manufacturer, Invetech Pty., of Melbourne, Australia, to manufacture its NovoGen MMX Bioprinter. Its bioprinting technology and surrounding intellectual property and commercial rights serve as a platform for product generation across multiple markets that employ cell- and tissue-based products and services.

 

The Company competes with Organogenesis, Advanced BioHealing, Tengion, Genzyme, HumaCyte and Cytograft Tissue Engineering.

Advisors’ Opinion:

  • [By Paul Ausick]A unique 3D printing stock is Organovo Holdings Inc. (NYSEMKT: ONVO). Shares are down more than 15% in 2014 after rising about 325% in 2013. The company is developing a 3D bioprinting technology that can create functional human tissues on demand for research and medical use. Organovo announced a first delivery of liver tissue in late January, well ahead of schedule, and the stock gained back some of its year-to-date losses. The company has been publicly traded for about a year and a half, and the stock hit a post-IPO high of $13.65 in November. It closed on Friday at $9.35. There is no price target on the stock, and the company is not expected to post positive earnings at least through 2015. In terms of market cap, though, Organovo ranks fourth among the publicly traded 3D printing companies with a market value of nearly $728 million.
  • [By MONEYMORNING]During my July interview, Michael enthusiastically recommended 3D Systems Corp. (NYSE: DDD) and Organovo Holdings Inc. (NYSEMKT: ONVO). But he urged readers to take a wait-and-see approach with ExOne, saying the stock had just corrected.

Top Asian Stocks For 2014: Weatherford International Ltd(WFT)

Weatherford International Ltd. provides equipment and services used in the drilling, evaluation, completion, production, and intervention of oil and natural gas wells worldwide. It offers artificial lift systems, which include reciprocating rod lift systems, progressing cavity pumps, gas lift systems, hydraulic lift systems, plunger lift systems, hybrid lift systems, wellhead systems, and multiphase metering systems. The company also provides drilling services, including directional drilling, ?Secure Drilling? services, well testing, drilling-with-casing and drilling-with-liner systems, and surface logging systems; and well construction services, such as tubular running services, cementing products, liner systems, swellable products, solid tubular expandable technologies, and inflatable products and accessories. In addition, it designs and manufactures drilling jars, underreamers, rotating control devices, and other pressure-control equipment used in drilling oil and nat ural gas wells; and offers a selection of in-house or third-party manufactured equipment for the drilling, completion, and work over of oil and natural gas wells for operators and drilling contractors, as well as a line of completion tools and sand screens. Further, the company provides wireline and evaluation services; and re-entry, fishing, and thru-tubing services, as well as well abandonment and wellbore cleaning services; stimulation and chemicals, including fracturing and coiled tubing technologies, cement services, chemical systems, and drilling fluids; integrated drilling services; and pipeline and specialty services. It serves independent oil and natural gas producing companies. The company was founded in 1972 and is headquartered in Geneva, Switzerland.

Advisors’ Opinion:

  • [By Dimitra DeFotis]Adams’ partial list of potential losers:

    BP (BP) : the highest profile potential loser. It owns 19.75% of Russian energy giant Rosneft, which accounted a third of BP’s production in the fourth quarter. Sanctions that inhibit oil and gas flows to Europe, or banking/capital flows, would “hit Rosneft and BP early and hard.” An offset: there could be an uptick in demand for a pipeline 30% owned and operated by BP because it transports Azerbaijan oil through Georgia and Turkey to the Mediterranean — a southern route avoiding Georgia and Ukraine. Chevron (CVX) pipeline investments could be stymied. It also signed a 50-year agreement to explore for and develop oil and gas in western Ukraine, involving up to $10 billion of investment. “A Russian takeover spikes that deal,” Adams says. Oilfield services companies Halliburton (HAL), Baker Hughes (BHI), and Weatherford International (WFT) all do business in Russia that could be prohibited if it is labeled a rogue nation.The crisis in Ukraine and Russia’s tactics make U.S. assets look more secure and more valuable: some U.S. refiners that could export fuel, utility holding companies that could export liquefied natural gas, and related pipeline companies could see even more benefits, longer-term,  from the North American fracking and horizontal drilling boom. But approval of the TransCanada (TRP) Keystone XL pipeline is a necessary piece of that equation, Adams writes.

  • [By Canadian Value]– Weatherford International (WFT) which is a services company and a direct beneficiary of the boom in horizontal drilling and fracturing in the U.S.

Top Asian Stocks For 2014: Salix Pharmaceuticals Ltd (SLXP)

Salix Pharmaceuticals, Ltd., incorporated on December 31, 2001, is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract. As of December 31, 2012, the Company’s products included XIFAXAN, MOVIPREP, APRISO, RELISTOR, OSMOPREP, SOLESTA, DEFLUX, FULYZAQ, GIAZO, METOZOLV ODT, AZASAN, ANUSOL-HC, PROCTOCORT, PEPCID, DIURIL and COLAZAL. As of December 31, 2012, its primary product candidates under development included Rifaximin, Methylnaltrexone bromide oral, Budesonide foam and Rifaximin EIR. In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.

 

Xifaxan (rifaximin) tablets

 

Xifaxan is a gastrointestinal-specific oral antibiotic. The Food and Drug Administration ( FDA) approved Xifaxan 200 milligram for the treatment of patients 12 years of age and older with travelers’ diarrhea caused by noninvasive strains of E coli. Xifaxan 550 milligram was approved by the FDA for reduction in risk of overt hepatic encephalopathy (HE), recurrence in patients 18 years of age or older.

 

It launched Xifaxan 200milligram in the United States and Xifaxan 550 milligram using its own direct sales force. The Company is exploring potential additional indications, formulations, clinical trials and co-promotion arrangements to capitalize on the potential for Xifaxan, including its development program in irritable bowel syndrome.

 

In October 2012, the USPTO declared an interference action to determine the priority of invention between Cipla’s application related to amorphous rifaximin and Solmag SpA’s application directed to amorphous rifaximin. In February 2012, the FDA posted draft bioequivalence guidance for rifaximin 550 milligram tablets. The draft guidance for rifaximin 550 milligram tablets recommends that in addition to conducting the program outlined in the FDA posted draft guidance document for rifaximin 200 milligram tablets discussed above, a single-dose, three-way crossover in-vivo study of fasting bioequivalence with pharmacokinetic endpoints in both fasting and fed states be performed in the 550 milligram tablets. Additionally, the guidance stipulated that the formulation of the 550 milligram strength should be proportionally similar to that of the 200 milligram strength in order to file an ANDA for approval of a generic rifaximin 550 milligram tablet for the treatment of hepatic encephalopathy.

 

MoviPrep (PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid) oral solution

 

MoviPrep is a patent-protected, liquid polyethylene glycol-salt, or PEG, bowel cleansing product that the FDA approved. MoviPrep is indicated for bowel cleansing prior to colonoscopy, intestinal surgery and barium enema X-ray examinations.

 

Apriso (mesalamine) extended-release capsules 0.375 gram

 

Apriso is a locally-acting aminosalicylate and is the only delayed and extended release mesalamine product approved by the FDA for once-a-day dosing for the maintenance of remission of ulcerative colitis. Apriso is designed to provide for the distribution of the active ingredient beginning in the small bowel and continuing throughout the colon. The product’s prolonged release mechanism might allow them to expand the range of treatment options for ulcerative colitis.

 

Relistor (methylnaltrexone bromide)

 

Relistor Subcutaneous Injection is indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Relistor is approved for use in over 55 countries worldwide.

 

OsmoPrep and Visicol (sodium phosphate monobasic monohydrate, USP, sodium phosphate dibasic anhydrous, USP) tablets

 

Visicol and OsmoPrep tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. Visicol and OsmoPrep are the only, tablet bowel cleansing products approved by the FDA and marketed in the United States. OsmoPrep is a patented, second-generation tablet bowel cleansing product that the FDA approved. OsmoPrep offers potential benefits compared to Visico,l such as its lack of microcrystalline cellulose, smaller tablet size and possible lower dose administration.

 

Solesta

 

Solesta is a biocompatible tissue bulking agent, consisting of dextranomer microspheres and stabilized sodium hyaluronate. Solesta is indicated for the treatment of fecal incontinence in patients 18 years and older who have failed conservative therapy, such as diet, fiber therapy and/or anti-motility medications. It is the only injectable gel for this indication to be administered in an outpatient setting without the need for surgery or anesthesia.

 

Deflux

 

Deflux is a medical device indicated for children affected by Grades II-IV vesicoureteral reflux, a malformation of the urinary bladder that can result in severe infections of the kidneys and irreversible kidney damage. Deflux was granted premarket approval application (PMA) approval, and has been on the market in the United States.

 

Fulyzaq (crofelemer) delayed-release tablets

 

On December 31, 2012, the FDA granted marketing approval for this product, under the trade name Fulyzaq. Fulyzaq is indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. Fulyzaq should also be eligible for five years of marketing exclusivity from the date of FDA approval, and the product might be entitled to patent term restoration.

 

Giazo (balsalazide disodium) tablets

 

February 3, 2012, the FDA granted marketing approval for this product under the trade name Giazo. Giazo is indicated for the treatment of mildly to moderately active ulcerative colitis in male patients 18 years of age and older. It shipped Giazo to wholesalers in 2012.

 

Metozolv ODT (metoclopramide hydrochloride) 5 milligrams and 10 milligrams orally disintegrating tablets

 

METOZOLV ODT is indicated for the relief of symptomatic gastroesophageal reflux or short-term (4-12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy and diabetic gastroparesis or the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis.

 

Azasan (azathioprine) tablets

 

Azasan is an FDA-approved drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis. It launched the 75 and 100 milligrams dosage strengths of Azasan in the United States.

 

Anusol-HC and Proctocort (hydrocortisone) creams and suppositories

 

The Company acquired the right to sell Anusol-HC 2.5% (hydrocortisone USP) cream, Anusol-HC 25 milligrams (hydrocortisone acetate) rectal suppositories, Proctocort 1% (hydrocortisone USP) cream and Proctocort 30 mg (hydrocortisone acetate) rectal suppositories from King Pharmaceuticals, Inc. The two cream products are topical corticosteroids indicated for relief of the inflammatory and pruritic, or itching, manifestations of corticosteroid-responsive dermatoses. The two suppository products are indicated for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic ulcerative colitis and other inflammatory conditions.

 

Pepcid (famotidine) for Oral Suspension and Diuril (Chlorothiazide)

 

Pepcid Oral Suspension is a widely known prescription pharmaceutical product indicated for several gastrointestinal indications, including the treatment of duodenal ulcer, benign gastric ulcer and gastro-esophageal reflux disease. Pepcid Oral Suspension and Diuril Oral Suspension, both liquid formulations of their solid dosage form counterparts, compete in a combined annual United States market concentrated in pediatric and hospitalized patient populations.

 

Colazal (balsalazide disodium) capsules

 

The Company launched Colazal to physicians in the United States. FDA approved Colazal for use in pediatric patients between 5 to 17 years of age with ulcerative colitis. The pediatric use of Colazal has been granted orphan drug designation. The Office of Generic Drugs, or OGD, approved three generic balsalazide capsule products.

 

The Company competes with GlaxoSmithKline plc, Giuliani S.p.A., Axcan Pharma, Inc., Abbott Laboratories, Warner Chilcott plc, Shire Pharmaceuticals Group plc, Pharmacia & Upjohn, Inc., Alaven Pharmaceutical LLC, Ferring Pharmaceuticals, Inc, Takeda Pharmaceutical Company Limited, Cumberland Pharmaceuticals, Inc, Prometheus Laboratories, Inc., Ranbaxy Pharmaceuticals, Ferndale Laboratories, GATE Pharmaceuticals , Nycomed , Medtronic, Inc., and Cubist Pharmaceuticals, Inc.

Advisors’ Opinion:

  • [By David Williamson]In this segment, health-care analyst David Williamson takes a look at the upcoming acquisition by Salix Pharmaceuticals (NASDAQ: SLXP  ) of Santarus (NASDAQ: SNTS  ) for about $2.6 billion. Salix is currently a maker of drugs for gastrointestinal diseases, and the immediately accretive deal will give Salix access to treatments for both diabetes and heartburn. Shares of both companies were up significantly on the news. David tells investors why shareholders should be pleased with this deal on both ends and what he thinks of the stock going forward.
  • [By Jake L’Ecuyer]Equities Trading UP
    Santarus (NASDAQ: SNTS) shot up 37.95 percent to $32.03 after Salix Pharmaceuticals (NASDAQ: SLXP) announced its plans to buy Santarus for around $2.12 billion. Santarus and Pharming also announced new data from open-label repeat treatment study with RUCONEST.
  • [By Paul Ausick]Stocks on the Move: Twitter Inc. (NYSE: TWTR) is down 7.3% at $41.64 on its second day of trading and word is that some hedge funds and traders are looking to borrow shares. Santarus Inc. (NASDAQ: SNTS) is up 37.6% at $31.95 after agreeing late Thursday night to an acquisition by Salix Pharmaceuticals Inc. (NASDAQ: SLXP) for $2.6 billion in cash.
  • [By Lisa Levin]Santarus (NASDAQ: SNTS) shares surged 37.64% to touch a new 52-week high of $31.96 after Salix Pharmaceuticals (NASDAQ: SLXP) announced its plans to buy Santarus for around $2.12 billion. Santarus and Pharming also announced new data from open-label repeat treatment study with RUCONEST.

Top Asian Stocks For 2014: Salient MLP And Energy Infrastructure Fund (SMF)

 

Salient MLP and Energy Infrastructure Fund (the Fund), is an organized, non-diversified, closed-end management investment company. Its investment objective is to provide a high level of total return with an emphasis on making quarterly cash distributions (Distributions) to its shareholders. The Fund seeks to provide its shareholders with a tax-efficient vehicle to invest in a portfolio of energy infrastructure companies that own midstream and other energy assets. The Fund will invest at least 80% of its total assets in securities of companies in the Midstream/Energy Sector, consisting of Midstream MLPs, Midstream Companies, Other MLPs and Other Energy Companies. It will invest in equity securities, such as common units, preferred units, subordinated units, general partner interests, common shares, preferred shares and convertible securities in MLPs, Midstream Companies and Other Energy Companies. The Fund is managed by Salient Capital Advisors, LLC. Advisors’ Opinion:

  • [By Eric Lam]Semafo (SMF) jumped 4.8 percent to C$2.60 and Iamgold gained 2.1 percent to C$4.20 as 21 of 24 members of the S&P/TSX Gold Index increased. Gold rose from a five-month low as investors weighed the outlook for reduced U.S. stimulus as early as next week against speculation physical demand may increase at lower prices. Gold for February delivery advanced 0.6 percent in New York.

Top Asian Stocks For 2014: JDS Uniphase Corporation(JDSU)

JDS Uniphase Corporation provides communications test and measurement solutions, and optical products for telecommunications service providers, wireless operators, cable operators, network-equipment manufacturers, and enterprises worldwide. The company?s Communications Test and Measurement segment supplies instruments, software, and services to enable the design, deployment, and maintenance of communication equipment and networks. Its product portfolio consists of test tools, platforms, software, and services for wireless and fixed networks. The company?s Communications and Commercial Optical Products segment offers components, modules, subsystems, and solutions that are used by communications equipment providers for telecommunications and enterprise data communications. This segment?s products comprise transmitters, receivers, amplifiers, ROADMs, optical transceivers, multiplexers and demultiplexers, switches, optical-performance monitors and couplers, splitters, and circ ulators, which enable the transmission of video, audio, and text data through fiber-optic cables. It also provides various laser products, including diode, direct-diode, diode-pumped solid-state, fiber, and gas lasers for micromachining, materials processing, bioinstrumentation, consumer electronics, graphics, medical/dental, and optical pumping; and photovoltaic products, such as concentrated photovoltaic cells and receivers for generating energy from sunlight, as well as fiber optic-based systems for delivering and measuring electrical power. The company?s Advanced Optical Technologies segment offers optical solutions for security and brand-differentiation applications; and thin film coatings for a range of public and private-sector markets. This segment also provides multilayer product-security solutions that deliver overt, covert, forensic, and digital product and document verification. JDS Uniphase Corporation was founded in 1979 and is headquartered in Milpitas, Califo rnia.

Advisors’ Opinion:

  • [By Dan Caplinger]Facebook certainly took the spotlight in the decision from S&P Dow Jones Indices to include the social media giant in the S&P 500. But lost in the Facebook news was the fact that Alliance Data Systems (NYSE: ADS  ) and Mohawk Industries (NYSE: MHK  ) also gained admission to the prestigious index, while Abercrombie & Fitch (NYSE: ANF  ) , JDS Uniphase (NASDAQ: JDSU  ) , and Teradyne (NYSE: TER  ) made their exit. Let’s take a closer look at the other winners and losers in the Facebook index shuffle.
  • [By James O’Toole]S&P also announced Wednesday that clothing retailer Abercrombie & Fitch (ANF) and communication technology firm JDS Uniphase Corp. (JDSU) will be leaving the index, to be replaced by Alliance Data Systems (ADS) and floor-covering producer Mohawk Industries (MHK, Fortune 500).

Top Asian Stocks For 2014: Oculus Innovative Sciences Inc.(OCLS)

Oculus Innovative Sciences, Inc. develops, manufactures, and markets tissue care products that prevent and treat infections in open wounds and skin care, as well as, through a separate mechanism of action, heal wounds while reducing the need for antibiotics. The company, through its platform technology, Microcyn, a solution of electrically charged oxychlorine small molecules treats organisms that cause disease, which include viruses, fungi, spores, and antibiotic-resistant strains of bacteria, such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus in wounds, as well as Clostridium difficile. It sells Microcyn technology-based human wound care products as prescription and over-the-counter products. The company markets its products through sales force and distributors in the United States, Mexico, Europe, and internationally. Oculus Innovative Sciences, Inc. offers its products to pharmacies; care centers; hospitals; nursing homes; urgent c are clinics; home healthcare; physicians; nurses; and other healthcare practitioners who are the primary caregivers to patients being treated for acute or chronic wounds or undergoing surgical procedures, as well as to dermatologists for treatment of various skin afflictions. The company was formerly known as Micromed Laboratories, Inc. and changed its name to Oculus Innovative Sciences, Inc. in August 2001. Oculus Innovative Sciences was incorporated in 1999 and is based in Petaluma, California.

Advisors’ Opinion:

  • [By John Udovich]Small cap stocks Derma Sciences Inc (NASDAQ: DSCI), Oculus Innovative Sciences, Inc (NASDAQ: OCLS) and Arch Therapeutics Inc (OTCBB: ARTH) specialize or have a focus on wound care – a medical problem that has plagued mankind since the dawn of time. After all and think back to our Civil War when disease along with infections resulting from improper wound care probably killed more soldiers than actual battles. Even today, infection after surgery or after receiving a wound or injury of any kind is still a constant threat. And then there is the scaring that can result from any sort of invasive surgery or injury. With those thoughts in mind, here are three small cap wound care stocks trying address these problems:

Top Asian Stocks For 2014: Genesis Energy LP (GEL)

Genesis Energy, L.P. (Genesis) is a limited partnership focused on the midstream segment of the oil and gas industry in the Gulf Coast region of the United States, primarily Texas, Louisiana, Arkansas, Mississippi, Alabama, Florida and in the Gulf of Mexico. The Company has a portfolio of customers, operations and assets, including pipelines, refinery-related plants, storage tanks and terminals, barges and trucks. Genesis provides an integrated range of services to refineries, oil, natural gas and carbon dioxide (CO2) producers, industrial and commercial enterprises that use sodium hydrosulfide (NaHS) and caustic soda, and businesses that use CO2 and other industrial gases. The Company operates in three segments: Pipeline Transportation, Refinery Services, and Supply and Logistics. In August 2011, the Company acquired black oil barge transportation business of Florida Marine Transporters, Inc. In November 2011, it acquired a 90% interest in a 3,500 barrel per day refinery located in Converse County, Wyoming, including 300 miles of abandoned 3- 6 pipeline. On January 3, 2012, it acquired interests in several Gulf of Mexico crude oil pipeline systems, including its 28% interest in the Poseidon pipeline system, its 29% interest in the Odyssey pipeline system, and its 23% interest in the Eugene Island pipeline system. In August 2013, the Company announced that it has completed the acquisition of all the assets of the downstream transportation business of Hornbeck Offshore Transportation, LLC (Hornbeck).

 

Pipeline Transportation

 

The Company transports crude oil and carbon dioxide (CO2) for others for a fee in the Gulf Coast region of the United States through approximately 550 miles of pipeline. Its Pipeline Transportation segment owns and operates three crude oil common carrier pipelines and two CO2 pipelines. Its 235-mile Mississippi System provides shippers of crude oil in Mississippi indirect access to refineries, pipelines, storage terminals and other crude oil infrastructure located in the Midwest. Its 100-mile Jay System originates in southern Alabama and the panhandle of Florida and provides crude oil shippers access to refineries, pipelines and storage near Mobile, Alabama. The Company’s 90-mile Texas System transports crude oil from West Columbia to several delivery points near Houston. Its crude oil pipeline systems include access to a total of approximately 0.7 million barrels of crude oil storage.

 

The Company’s Free State Pipeline is an 86-mile, 20 CO2 pipelines that extends from CO2 source fields near Jackson, Mississippi, to oil fields in eastern Mississippi. It has a twenty-year transportation services agreement (through 2028) related to the transportation of CO2 on its Free State Pipeline.

 

Refinery Services

 

Genesis provides services to eight refining operations located in Texas, Louisiana and Arkansas, which operates storage and transportation assets in relation to its business and sell NaHS and caustic soda to industrial and commercial companies. The refinery services involve processing refiner’s sulfur (sour) gas streams to remove the sulfur. The refinery services also include terminals and it utilizes railcars, ships, barges and trucks to transport product. Its contracts are long-term in nature and have an average remaining term of four years.

 

Supply and Logistics

 

The Company provides services to Gulf Coast oil and gas producers and refineries through a combination of purchasing, transporting, storing, blending and marketing of crude oil and refined products, primarily fuel oil. It has access to a range of more than 250 trucks, 350 trailers and 50 barges with 1.5 million barrels of terminal storage capacity in multiple locations along the Gulf Coast, as well as capacity associated with its three common carrier crude oil pipelines.

Advisors’ Opinion:

  • [By Dividends4Life]This week a few companies answered the call and rewarded their shareholders with higher cash dividends:

    Consolidated Edison Inc. (ED) engages in regulated electric, gas, and steam delivery businesses. January 16th the company increased its quarterly dividend 2.4% to $0.63 per share. The dividend is payable March 15, 2014, to stockholders of record on February 12, 2014. The yield based on the new payout is 4.7%.

    Cousins Properties Incorporated (CUZ), a real estate investment trust (REIT), owns, develops, and manages real estate portfolio, as well as performs certain real estate-related services. January 16th the company increased its quarterly dividend 66.7% to $0.075 per share. The dividend is payable February 24, 2014, to stockholders of record on February 10, 2014. The yield based on the new payout is 2.8%.

    Wisconsin Energy Corporation (WEC) generates and distributes electric energy, as well as distributes natural gas. The company operates in two segments, Utility Energy and Non-Utility Energy. January 16th the company increased its quarterly dividend 2% to $0.3900 per share. The dividend is payable March 1, 2014, to stockholders of record on February 14, 2014. The yield based on the new payout is 3.8%.

    BlackRock Inc. (BLK) is a publicly owned investment manager. The firm primarily provides its services to institutional, intermediary, and individual investors. January 16th the company increased its quarterly dividend 14.9% to $1.93 per share. The dividend is payable March 24, 2014, to stockholders of record on March 7, 2014. The yield based on the new payout is 2.4%.

    ONEOK Inc. (OKE) operates as a diversified energy company in the United States. January 15th the company increased its quarterly dividend 5.3% to $0.40 per share. The dividend is payable February 18, 2014, to stockholders of record on February 10, 2014. The yield based on the new payout is 2.5%.

    Omega Healthcare Investors Inc. (OHI) is a real es

  • [By Aimee Duffy]Distributions are incredibly important to master limited partnerships — they are the reason many investors buy in, and ultimately what drive the market performance for this asset class. As news of distribution increases trickle in for the third quarter, Fool.com contributor Aimee Duffy takes a look at the payouts from Genesis Energy (NYSE: GEL  ) , Plains All American Pipeline (NYSE: PAA  ) , and Memorial Production Partners (NASDAQ: MEMP  ) , as all three MLPs are leading the way with the biggest distribution increases.
  • [By Marc Bastow]Midstream oil and gas MLP Genesis Energy (GEL) raised its quarterly distribution 2.5% to 52.25 cents per share, payable Nov. 14 to unitholders of record as of Nov. 1.
    GEL Dividend Yield: 4.25%
  • [By Matt DiLallo]Genesis Energy (NYSE: GEL  )
    The final stock to get on your dividend watchlist is Genesis Energy. The company’s business is split between pipeline transportation, refinery services, and supply and logistics, as you can see on the slide below. In addition to the assets it already has on the books, Genesis has a number of projects in the pipeline to drive future growth. Genesis estimates that these projects will enable it to provide distribution growth to investors in the low double digits well into the future. Genesis has quite the history to back those estimates up as the company has 31 consecutive quarters of distribution increases, including 26 which were more than 10%. That’s what makes this dividend-paying stock one to watch.